1Nemcekova E, Nosalova G, Franova S. Ambroxol and protective reflexes of the respiratory tract [J]. Bratisl Lek lAsty,1998, 99(2): 111.
2Gilissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy [J]. Respir Med, 1998, 92 (4)- 609.
3Bing Z, Reddy SA, Ren Y, et al. Purification and characterization of the serum amyloid A3 enhancer factor [J]. J Biol Chem, 1999, 274(35): 24649.
4Boylan MT, Crockard AD, Duddy ME. Intefferon-betala administration results in a transient increase of serum amyloid A protein and C-reactive protein: comparison with other markets of inflammation [J]. Immunol Lett, 2001, 75(3): 191.
5Yamada T. SAA: a concise review of biology, assay methods and clinical usefulness [J]. Clin Chem Lab Med, 1999, 37(4): 381.
6Enguix A, Rey C, Concba A. Comparison of pmcalcitonin with C-reactive protein and serum amyloid A for the early diagnosis of bacteria] sepsis in critica]ly ill neonates and children [J]. Intensive Care Med, 2001, 27(1): 211.
7Nemcekova E, Nosalova G, Franova S. Ambroxol and protective reflexes of the respiratory tract [J]. Bratisl Lek Listy, 1998, 99(2): 111.
3Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy,and Immunology. Chest, 2005; 127(1): 335-371.
4Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.Br J Clin Pharmacol,2003; 56(6):600-612.
5Juni P, Altman DG, Egger M. Systematic reviews in health care:Assessing the quality of controlled clinical trials.BMJ, 2001;323(7303):42-46.
6Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias.Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.JAMA, 1995; 273(5): 408-412.
7Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet, 1998; 352(9128): 609-613.
8Merkus P, Romeijn SG, Verhoef JC, et al. Classification of cilio-inhibiting effects of nasal drugs.Laryngoscope, 2001 111(4 Pt 1):595-602.
9Haidl P. Nebulized treatment-What is evidence-based?Atemwegsund Lungenkrankheiten,2004; 30(9): 432-439.
